Elahe Zeinali - Department of Immunology and Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
Vahid Bagheri - Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
Esmaeil Rostami - Department of Laboratory Sciences, Faculty of Para- Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
Gholamreza Anani Sarab - Cellular & Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Resistant cells are a critical problem that reducetreatment efficacy of breast cancer. Nowadays,CIP۲A and PD-L۱ are considered as theraputicalchallenges in breast cancer, because ofresponsible for drug resistance and immuneevasion respectively. Hence, identifying agents tosuppress these factors is great of interest.Specifically, epigenetic drugs can be an effectiveapproach to alter the behavior of genes. Althoughvalproic acid (VPA) as a HDAC inhibitor hascertain anticancer properties but molecularmechanism of VPA in breast cancer cells remainsto be explored. In this study, we investigated drugeffects and molecular mechanisms of VPA,particularly its effect on CIP۲A and PD-L۱ inbreast cancer MCF-۷ cell line.In this study, MCF-۷ cells were treated withvarious concentration of VPA for ۲۴ h, ۴۸ h, and۷۲ h. The rate of cell viability was measured byMTT assay. Finally, gene expressions of CIP۲A,c-MYC, PI۳K, Akt, mTOR and PD-L۱ wereanalyzed by real time PCR and ΔCT method.

Valproic acid (VPA);histone deacetylase inhibitor(HDACi); CIP۲A, PD-L۱; breast cancer